Perspective Therapeutics updates VMT-α-NET Ph1/2a data and preliminary cash position

Perspective Therapeutics, Inc.

Preliminary cash & short-term investments as of Mar 31, 2026 disclosed; unaudited, subject to final adjustments.
VMT-α-NET Phase 1/2a data show durable disease control across all doses; responses deepen over time.
Company says profile supports potential registration study at current dose level.
Manufacturing update: daily production at regional sites for ready-to-administer 212Pb products.
Expanding pipeline includes CCK2R81 targeting and other solid tumor programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.